Form 4: 10x Genomics Grants 88,816 RSUs to President & CSO Hindson

10x Genomics, Inc. awarded 88,816 restricted stock units to Benjamin J. Hindson, President and Chief Scientific Officer, as part of his compensation.

Summary

• Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, Inc. (TXG), was granted 88,816 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs).
• The transaction date for this acquisition was February 26, 2026.
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
• Following this transaction, Benjamin J. Hindson directly beneficially owns 513,595 shares.
• The RSUs will vest in 12 equal quarterly installments, with the vesting schedule commencing on February 21, 2026, contingent on continued service.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine executive compensation event, generally positive for executive retention and alignment, with minimal immediate impact on the company's valuation.

Positives

• The RSU grant serves as an incentive for Benjamin J. Hindson, a key executive, aligning his interests with long-term shareholder value.
• This compensation structure helps in retaining critical talent within the company.

Negatives

• The future vesting of these RSUs will result in a slight dilution of existing shareholder equity.

Future Outlook

The filing indicates a future vesting schedule for the granted RSUs, with 1/12th of the units vesting on each quarterly anniversary measured from February 21, 2026, subject to the reporting person's continued service.

Industry Context

StockSavvy.ai notes that RSU grants are a standard component of executive compensation packages across the biotechnology and life sciences sectors, designed to incentivize long-term performance and executive retention.

Comparison to Industry Standards

• StockSavvy.ai observes that the use of Restricted Stock Units (RSUs) for executive compensation is a common practice in the biotechnology industry, comparable to compensation strategies employed by peers such as Illumina (ILMN) or Bio-Rad Laboratories (BIO).
• The vesting schedule, tied to continued service, is typical for such grants, aiming to retain key executives and align their interests with the company's long-term success.

Related Party Transactions

• The grant of Restricted Stock Units to Benjamin J. Hindson, an officer and director of 10x Genomics, Inc., constitutes a related party transaction as it involves compensation to a key management personnel.

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon vesting of the RSUs, but also benefits from incentivized and retained executive leadership.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• 1/12th of the 88,816 RSUs will vest on each quarterly anniversary measured from February 21, 2026, subject to Benjamin J. Hindson's continued service.

Key Dates

Recommendation

This Form 4 reports a standard RSU grant to a key executive, which is a routine compensation event and does not provide new information warranting a change in investment strategy for 10x Genomics. The transaction is an expected part of executive incentive programs.

Keywords

10x Genomics, TXG, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Benjamin J. Hindson, Stock Grant